Old Republic International Corporation, through its subsidiaries, provides insurance underwriting and related services primarily in the United States and Canada. The company operates in two segments, Specialty Insurance and Title Insurance. The Specialty Insurance segment offers accident and health, aviation, commercial auto, commercial multi-peril, commercial property, excess and surplus, general liability, home and auto warranty, inland marine, travel accident, and workers' compensation insurance products; and financial indemnity products for specialty coverages, including errors and omissions, fidelity, directors and officers, and surety. This segment provides its insurance products to businesses, state and local governments, and other institutions in transportation, commercial construction, healthcare, education, retail and wholesale trade, forest products, energy, general manufacturing, and financial services industries. The Title Insurance segment offers lenders' and owners' policies to real estate purchasers and investors based upon searches of the public records. This segment also provides escrow closing and construction disbursement services; and real estate information products, national default management services, and various other services pertaining to real estate transfers and loan transactions. Old Republic International Corporation was founded in 1923 and is based in Chicago, Illinois.

Old Republic International Corporation

Roth MKM analyst reiterated a Buy rating on Oric Pharmaceuticals today and set a price target of $15.00. Currently, the analyst consensus on Oric P...

Roth MKM Reaffirms Their Buy Rating on Oric Pharmaceuticals (ORIC)

In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Oric Pharmaceuticals, with a price target of $15.00. Accord...

Oppenheimer Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)

In a report released today, David Nierengarten from Wedbush maintained a Buy rating on Oric Pharmaceuticals, with a price target of $20.00. Accordi...

Wedbush Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)

Oric Pharmaceuticals ( ($ORIC) ) has issued an update. On December 6, 2025, Oric Pharmaceuticals presented an update on its enozertinib (ORIC-114) ...

Oric Pharmaceuticals Highlights Promising Enozertinib Trial Results

The latest announcement is out from Octopus Renewables Infrastructure Trust Plc ( ($GB:ORIT) ). Octopus Renewables Infrastructure Trust Plc announc...

Octopus Renewables Director Acquires Shares, Signaling Confidence

The latest update is out from Orica Limited ( ($AU:ORI) ). Orica Limited announced a change in the director’s interest, with Sanjiv Kumar Gandhi ac...

Orica Limited Announces Director’s Share Acquisition

The latest update is out from Orica Limited ( ($AU:ORI) ). Orica Limited has announced an update on its ongoing share buy-back program, reporting t...

Orica Limited Updates on Share Buy-Back Progress

Orica Limited ( ($AU:ORI) ) has issued an update. Orica Limited announced a change in director’s interest notice for Mr. Sanjeev Gandhi and a notif...

Orica Limited Addresses Administrative Oversight in Director’s Interest Notice

Orica Limited ( ($AU:ORI) ) just unveiled an announcement. Orica Limited has announced a change in the director’s interest, with Vikas Bansal acqui...

Orica Limited Announces Director’s Acquisition of Shares

Oric Pharmaceuticals Inc (ORIC) has disclosed a new risk, in the Employment / Personnel category. Oric Pharmaceuticals Inc.’s strategic pipeline pr...

Oric Pharmaceuticals’ 2025 Restructuring: Potential Risks and Financial Implications

J.P. Morgan analyst Lee Power maintained a Buy rating on Orica Limited on November 13 and set a price target of A$26.00. The company’s shares close...

J.P. Morgan Sticks to Its Buy Rating for Orica Limited (OCLDF)

Wedbush analyst David Nierengarten maintained a Buy rating on Oric Pharmaceuticals today and set a price target of $20.00. Nierengarten covers the ...

Morgans analyst Belinda Moore maintained a Buy rating on Orica Limited today and set a price target of A$28.00. According to TipRanks, Moore is a 4...

Morgans Remains a Buy on Orica Limited (OCLDF)

The latest announcement is out from Oric Pharmaceuticals ( ($ORIC) ). Oric Pharmaceuticals announced an update on their ORIC-944 clinical trials, h...

Oric Pharmaceuticals Reports Promising ORIC-944 Trial Results

Citi analyst William Park CPA maintained a Buy rating on Orica Limited today and set a price target of A$24.05. Park CPA covers the Industrials sec...

Orica Limited (OCLDF) Gets a Buy from Citi

An update from Orica Limited ( ($AU:ORI) ) is now available. Orica Limited has released its corporate governance statement for the financial year e...

Orica Limited Releases 2025 Corporate Governance Statement

The latest update is out from Orica Limited ( ($AU:ORI) ). Orica Limited has released its Corporate Governance Statement for the year ending Septem...

Orica Limited Upholds Strong Corporate Governance and Ethical Standards

The latest update is out from Orica Limited ( ($AU:ORI) ). Orica Limited reported a strong financial performance for the year ending September 2025...

Current Quarter	$0.89	Next Quarter	$0.86
Current Year	$3.26	Next Year	$3.45
QoQ Growth	-3.4%	YoY Growth	+5.8%
3Y EPS CAGR	N/A	Target Price	$46.50
Consensus	Buy	Upside	+6.5%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ORI	$43.66	+1.66%	698.76K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ORI	$43.66	+1.7%	698.76K
3
4
5
6

ORI

ORI

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get Old Republic International Corporation Data in Excel

Get Old Republic International Corporation Data in Excel